CannaVest Corp. (CANV) Financials Nov 14, 2014, 4:04

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
CannaVest Corp. (CANV) Financials Nov 14, 2014, 4:04 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for CannaVest Corp.


Fiscal year is January-December. All values USD millions. 2010 2011 2012 2013 5-year trend
Sales/Revenue - 0 0 0 2.15M
Cost of Goods Sold (COGS) incl. D&A - 0 0 0 1.63M
COGS excluding D&A - 0 0 0 866,716
Depreciation & Amortization Expense - 0 0 0 767,254
Depreciation - - 0 0 13,754
Amortization of Intangibles - 0 0 0 753,500
Gross Income - 0 0 0 520,093
2010 2011 2012 2013 5-year trend
SG&A Expense - 8,425 88,092 43,018 2.14M
Research & Development - 0 0 0 524,476
Other SG&A - 8,425 88,092 43,018 1.61M
Other Operating Expense - 0 0 0 0
Unusual Expense - 0 0 0 0
EBIT after Unusual Expense - 0 0 0 0
Non Operating Income/Expense - 0 (2,088) (2,593) 0
Non-Operating Interest Income - - - 0 0
Equity in Affiliates (Pretax) - 0 0 - (310,754)
Interest Expense - 0 0 0 372,109
Gross Interest Expense - 0 0 0 372,109
Interest Capitalized - 0 0 0 0
Pretax Income - (8,425) (90,180) (45,611) (2.3M)
Income Tax - 0 0 0 0
Income Tax - Current Domestic - 0 0 - -
Income Tax - Current Foreign - 0 0 - -
Income Tax - Deferred Domestic - 0 0 - -
Income Tax - Deferred Foreign - 0 0 - -
Income Tax Credits - 0 0 - -
Equity in Affiliates - 0 0 0 0
Other After Tax Income (Expense) - 0 0 0 0
Consolidated Net Income - (8,425) (90,180) (45,611) (2.3M)
Minority Interest Expense - 0 0 0 0
Net Income - (8,425) (90,180) (45,611) (2.3M)
Extraordinaries & Discontinued Operations - 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets - 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations - 0 0 0 0
Net Income After Extraordinaries - (8,425) (90,180) (45,611) (2.3M)
Preferred Dividends - 0 0 0 0
Net Income Available to Common - (8,425) (90,180) (45,611) (2.3M)
EPS (Basic) - () (0.01) (0.01) (0.23)
Basic Shares Outstanding - 7M 6.97M 7M 9.88M
EPS (Diluted) - () (0.01) (0.01) (0.23)
Diluted Shares Outstanding - 7M 6.97M 7M 9.88M
EBITDA - (8,425) (88,092) (43,018) (850,079)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Rocket Lab Corp: Explosive Growth and Stock Momentum

Updated Category News Views 285

Rocket Lab's Recent Stock Surge Shares of Rocket Lab Corp (NASDAQ: RKLB) have hit a remarkable all-time high, showcasing the company's increasing prominence in the space launch industry. This unprecedented rise in stock value can be largely attributed to a series of lucrative contracts that have instilled confidence among investors. Positive Developments Fueling Investor...

Continue Reading
Michaels Unveils Innovative In-Store Experiences for Creativity

Updated Category News Views 321

Michaels Expands Offerings with The Knit & Sew Shop and The Party Shop Michaels continues to be a prominent name in North America by introducing exciting new store-in-store experiences known as The Knit & Sew Shop and The Party Shop. This strategic move not only enriches the shopping experience for customers, but also reinforces Michaels' position as the largest specialty...

Continue Reading
Liberty Hill Foundation Expands Leadership for Future Impact

Updated Category News Views 109

Liberty Hill Foundation Expands Leadership Team As Liberty Hill Foundation marks an important milestone, it has made significant changes to its executive leadership to bolster its efforts in supporting grassroots organizations in Los Angeles. This transformation is aimed at ensuring long-term sustainability and societal impact during a crucial time in history. New...

Continue Reading
GSK's RSV and Shingles Vaccine Trial Shows Promising Results

Updated Category News Views 124

GSK plc Shares Encouraging Results on Combined RSV and Shingles Vaccines GSK plc (LSE/NYSE: GSK) has just announced encouraging topline findings from an important phase 3 trial involving adults aged 50 and older. This study assessed the immunogenicity, reactogenicity, and safety of AREXVY, a vaccine for respiratory syncytial virus (RSV), when given together with SHINGRIX,...

Continue Reading
Investors Urged to Act as Hasbro Faces Class Action Lawsuit

Updated Category News Views 141

Investors Should Take Action Regarding Hasbro, Inc. Attention investors! A recent announcement has surfaced indicating a class action lawsuit against Hasbro, Inc. This legal action is initiated by Bronstein, Gewirtz & Grossman, LLC, a well-known law firm in the field of securities fraud. The firm aims to represent those individuals and entities that may have suffered...

Continue Reading